脐血单个核细胞和脐带间充质干细胞治疗儿童孤独症的安全性与有效性

背景：目前国内外尚没有治疗儿童孤独症的金标准,康复治疗效果不佳。 目的：评价脐血单个核细胞和脐带间充质干细胞治疗儿童孤独症的临床安全性和有效性。 方法：37例儿童孤独症患者非随机分为脐血组、混合组和对照组。脐血组应用脐血单个核细胞加康复训练治疗;混合组联合应用脐血单个核细胞和脐带间充质干细胞加康复训练治疗;对照组单纯行康复训练治疗。脐血组和混合组患者在干细胞治疗前和首次治疗后1,2,6个月分别行相关指标实验室检查,并观察有无不良反应发生。3组患者在治疗前和首次治疗后1,2,6个月分别行儿童孤独症评定量表(CARS)和异常行为量表(ABC)评估。 结果与结论：脐血组和混合组患者在干细胞治疗前和首次治疗后1,2,6个月相关指标实验室检查未发现有意义异常变化,干细胞治疗后无严重不良反应发生;根据CARS和ABC评分,3组治疗均有效,其疗效比较：混合组优于脐血组,脐血组优于对照组。

Safety and efficacy of cord blood mononuclear cells and umbilical cord mesenchymal stem cells therapy for childhood autism

BACKGROUND:There is no clear standard for curing autism, and the effect of rehabilitation treatment is not satisfied. OBJECTIVE:To evaluate the safety and efficacy of cord blood mononuclear cells (MNCs) and umbilical cord mesenchymal stem cells (MSCs) in treating autistic children. METHODS:Thirty-seven children with autism were divided into MNCs treatment (MNCs plus rehabilitation treatment), MNCs combined with MSCs treatment (MNCs combined with MSCs plus rehabilitation treatment) and control (rehabilitation treatment alone) groups. Related laboratory examinations were performed for each group before treatment, 1, 2 and 6 months after treatment to observe adverse effects. Childhood Autism Rating Scale and Aberrant Behavior Checklist were employed to assess the children of autism. RESULTS AND CONCLUSION:There was no statistical difference between MNCs treatment group and MNCs combined with MSCs treatment group in laboratory examinations at each time point, and no adverse effects were observed in two groups. Childhood Autism Rating Scale and Aberrant Behavior Checklist showed that three treatment presented efficacy, but the MNCs combined with MSCs treatment group was the best, followed by MNCs treatment group, and then control group.